News for MannKind Corporation (MNKD)

Discover MannKind's Q4 earnings results on Feb 26! Analysts predict $0.03 EPS (+50% Y/Y) & $74.99M revenue (+28.3%).

Get a deeper insight into the potential performance of MannKind (MNKD) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

**media[544997]**

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation ( MNKD), a company focused on the development and commerci

Dominic Marasco, RPh, joins the company as President, Endocrine Business Unit, effective January 6, 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 0

**media[507419]**

About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income nations. Every year, diabetes directly causes 1.5 million deaths on average.

MannKind (MNKD) stock was up 10% in midday trading Friday after Wells Fargo initiated coverage of the stock with an overweight rating and a price target of $9. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

RBC has upgraded MannKind (MNKD) to outperform from sector perform, citing the company’s Tyvaso DPI royalty revenue opportunity and orphan lung pipeline. Read more here.

MannKind (MNKD) reduces debt by $194M through exchange of convertible notes for stock and cash, improving financial position.

MannKind Corporation is focused on inhaled therapies for endocrine and orphan lung diseases. Check out my recommendation for MNKD stock.

Increase in prevalence of diabetes, rise in awareness and screening programs for diabetes, and rise in R&D activities are the major factors which drive the...

Expect earnings reports, and CEO commentaries, to drive the market action.

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...

Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday.

Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results.

MannKind (MNKD) needs to decide if Afrezza will be a reliable source of revenue or a drag on future revenues. Click here to read more.

/PRNewswire/ -- The "Global Insulin Delivery Devices Market by Type (Insulin Pens [Reusable, Disposable], Insulin Pumps (Tethered, Tubeless), Insulin Syringes,...